5:00 PM
 | 
Jan 02, 2018
 |  BC Extra  |  Preclinical News

CYLD expression could slow progression of NASH

In a paper published in Nature Medicine, researchers at Wuhan University and Weill Cornell Medicine found that increasing expression of the deubiquitinating enzyme cylindromatosis turban tumor syndrome (CYLD) reversed progression of non-alcoholic steatohepatitis (NASH) in animal models.

Deubiquitinating enzymes (DUBs) remove polyubiquitin chains from proteins, preventing their degradation by the proteasome. Based on their ability to control protein levels, DUBs are emerging as...

Read the full 300 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >